Table 5.
Small molecules with SIRT-activating or SIRT-inhibiting activities.
| Compound name | Target | Disease | Fibrosis-related output | Status | Ref./identifier |
| SIRT activators | |||||
| Resveratrol | SIRT1, SIRT3, SIRT5 | Osteoarthritis | Increases IL-10 to reprogramme macrophages | III clinical trial | 167 |
| Sildenafil | SIRT1, SIRT3 | Huntington | Increases GSH and SOD and decreases TNF-α | II clinical trial | 168 |
| JP-022 | SIRT1, SIRT2, SIRT3 | Alzheimer's diseases | _ | Pre-clinical | WO2016028910A1 |
| SRT1460 | SIRT1 | Diabetes mellitus, type 2 | _ | Pre-clinical | CN103145738A |
| R-Cu | SIRT1 | Alzheimer diseases | _ | II clinical trial | CTRI/2019/07/020289 |
| SIRT inhibitors | |||||
| MDL-800 | SIRT6 | Hepatocellular carcinoma | Inhibits phosphorylation and nuclear localization of SMAD2 | Pre-clinical | 84 |
| EH-301 | SIRT5 | Acute kidney injury | Inhibits skin fibroblasts | II clinical trial | 169 |
| SP-624 | SIRT6 | Depressive disorder | _ | II clinical trial | NCT04510298, NCT04479852 |
| AGK2 | SIRT2 | Tumor | _ | Pre-clinical | 170 |
| Cambinol | Pan | Leukoencephalopathy, progressive multifocal | _ | Drug discovery | 171 |
| Ex-527 | SIRT1 | Tumor | _ | Drug discovery | 172 |